Loading...

ABUS ARBUTUS BIOPHARMA CORP Company Mergers 8-K Filing

RBTS

BS

ARBUTUS BIOPHARMA CORP

(ABUS)

2025 8-K

Show Summary

Summary

Termination of Agreement

Financial Statements

Presentation of Research Fi...

Conference Presentations

Management Changes

Financial Results

Patent Litigation

Board Restructuring

Financial Update

Clinical Trial Results

Q3 2024 Results

Clinical Data Presentation

Management Change

Regulation FD Disclosure

Financial Results and Corpo...

Clinical Trial Results

Clinical Trial Results

Shareholder Meeting Approval

Announcement of Abstract Ac...

Financial Results and Corpo...

Retirement of Chief Scienti...

Financial Results and Corpo...

Financial Results

Management Changes

Poster Presentation and Cor...

Financial Results, Workforc...

Retirement and Appointment

Announcement of Data Presen...

Pipeline Updates

Financial Results and Corpo...

Clinical Trial Update

Clinical Trial Results

Announcement of Poster Pres...

Management Changes

Financial Results and Corpo...

Clinical Data Presentation

Announcement of Abstract Ac...

Lawsuit against Pfizer and ...

Preclinical Data Announcement

Financial Results and Corpo...

Resignation of Director

External Links:

On June 20, 2025, Arbutus Biopharma Corporation terminated its license agreement with Qilu Pharmaceutical, regaining rights to its lead compound imdusiran in Greater China and Taiwan, with no payments made for the termination.

AI Assistant

ARBUTUS BIOPHARMA CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.